Loading…
Hosted by IDEA Pharma, SAI MedPartners · 🇺🇸 US · EN · 72 episodes
Established thought leaders with verified media credentials.
IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. The podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare.Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and unlock competitive advantage through differentiated thinking.Questions We Explore* What is asymmetric learning, and how does it fuel pharma innovation?* Why do some organizations outpace others—and what can we learn from them?* How can we overcome barriers to meaningful progress in healthcare?* What’s broken in traditional innovation models—and how do we fix it?🎧 Listen and subscribe on all major platforms.
IDEA Pharma, SAI MedPartners hosts IDEA Collider: Innovation & Asymmetric Learning in Pharma, a science show with 72 episodes published.
Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and COO of Immunic, to discuss the rapidly evolving landscape of Multiple Sclerosis (MS) treatment. For 30
Welcome to a special edition of IDEA Collider’s "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic research expert, to discuss the rapidly sh
Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Sue Wood, a senior expert at IDEA Pharma with a PhD from Oxford and decades of experience translating complex scientific concepts i
Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic Consulting and Analytics, to discuss the
Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how P
In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next frontier in cancer treatment—particularly fo
In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech’s most complex transformations. After the rapid rise and decli
In this episode of IDEA Collider, host Mike Rea sits down with Nello Mainolfi, founder and CEO of Kymera Therapeutics. Nello shares his journey from medicinal chemist to biotech founder and discusses the opportunities an
In this episode of the IDEA Collider podcast, industry experts explore the evolving role of AI in Competitive Intelligence (CI) in pharmaceutical and biotech strategy — and how organizations can move beyond data collecti
In this episode of IDEA Collider , host Mike Rea sits down with Michelle Werner , CEO of Alltrna , to explore a groundbreaking approach that could transform how we treat thousands of genetic diseases. Michelle shares how
In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the Reblozyl project, undertaken in collaboration with Acceleron and Celgene. Rick, the head of Growth and Innovatio
In this episode of IDEA Collider , host Mike Rea speaks with Dr. Sekar Kathiresan , founder of Verve Therapeutics and now part of Eli Lilly , about one of the boldest ideas in modern medicine: using one-time gene editing
In this episode of IDEA Collider, we are joined by Alex Telford, a biotech founder, writer, and thinker based in the San Francisco Bay Area. As the co-founder of Convoke Bio, Alex discusses his journey from studying bioc
In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute, through roles at Roche, to overseeing glob
In this insightful episode of IDEA Collider , Mike welcomes Mathai Mammen, Chairman and CEO of Parabilis Medicines. Mathai shares his extensive journey through academia, MD PhD program at Harvard, co-founding Theravance,
In this episode of Idea Collider , host Mike Rea interviews Paul Peter Tak, CEO of Candel Therapeutics, discussing his remarkable journey from a clinician in Amsterdam to leading cutting-edge biotech companies. Paul shar
In this episode of Idea Collider, we sit down with Susan Galbraith from AstraZeneca, a leading figure in oncology R&D. Susan shares her journey from medical training in Manchester and Cambridge to spearheading transforma
In this episode of IDEA Collider, we dive into the world of biotech innovation with John Maraganore, former CEO of Alnylam Pharmaceuticals. Recognized as a trailblazer, John transformed RNA interference from a scientific
We are excited to tell you more about the IDEA Pharma and Exploristics partnership. IDEA’s COO, Jacqui Barendregt, asked Exploristics Founder and CEO Aiden Flynn five key questions about the innovative service model and,
Welcome to another episode of Idea Collider with your host, Mike Rea. In this engaging conversation, we delve into the world of pharmaceutical innovation and collaboration. Our guest, Dr. Nedim Pipic, a pharmaceutical ex
Alex Gray
storyboard artist and director
2 appearances on this show
Michelle Werner
CEO/Partner · Flagship Pioneering
1 appearance on this show
Rita McGrath
Author, Top Management Thinker, and Strategic Leader · Columbia Business School
1 appearance on this show
Steven Johnson
first-generation funeral director · City of Suffolk Department of Fire & Rescue
1 appearance on this show
John Tsai
MD · eXp Canada
1 appearance on this show
Rob Scott
Chief Operating Officer · Dillingham Bible Fellowship
1 appearance on this show
Gerald Posner
investigative journalist and attorney
2 appearances on this show
Jane Metcalfe
The Human Immunome Project
1 appearance on this show
Jeremy Levin
Dr. · Ovid Therapeutics
1 appearance on this show
Annie Duke
former world-champion poker player turned cognitive psychologist
1 appearance on this show
Peter Kolchinsky
Scientist, investor, author, founder of No Patient Left Behind, co-founder of RA Capital Management
1 appearance on this show
John Carroll
Senior Vice President and Head of Annuities · St. Francis High School Golden Knights
1 appearance on this show
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
IDEA Collider: Innovation & Asymmetric Learning in Pharma has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
IDEA Collider: Innovation & Asymmetric Learning in Pharma is hosted by IDEA Pharma, SAI MedPartners. The show is categorised under science (life) and has published 72 episodes.
IDEA Collider: Innovation & Asymmetric Learning in Pharma has published 72 episodes.
IDEA Collider: Innovation & Asymmetric Learning in Pharma regularly covers science, life, business. It sits in the science category, with a life focus.
IDEA Collider: Innovation & Asymmetric Learning in Pharma is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
IDEA Collider: Innovation & Asymmetric Learning in Pharma hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of IDEA Collider: Innovation & Asymmetric Learning in Pharma average 44 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates IDEA Collider: Innovation & Asymmetric Learning in Pharma's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 5 days ago.